Left behind: The potential impact of CFTR modulators on racial and ethnic disparities in cystic fibrosis

Pharmacogenetic actionability and medication prescribing in people with cystic fibrosis

“…This study is limited by the retrospective nature of the medication data acquisition and a relatively small sample size. Possibly owed to the small sample size, only 6% of this cohort were of racial/ethnic minority compared to 18% of PwCF reported in the Cystic Fibrosis Foundation Registry 24 . This under‐representation has the potential for underestimating the true impact PGx testing could have among the CF population 17 .…”

“…Possibly owed to the small sample size, only 6% of this cohort were of racial/ethnic minority compared to 18% of PwCF reported in the Cystic Fibrosis Foundation Registry. 24 This under‐representation has the potential for underestimating the true impact PGx testing could have among the CF population. 17 There are also limitations due to the dependence on documented medications and medication responses, which may not reflect all medications taken by the participants or all adverse drug responses experienced.…”

Comparison of continuous glucose monitoring to reference standard oral glucose tolerance test for the detection of dysglycemia in cystic Fibrosis: A systematic review

“…We found two studies reported CGM hyperglycemia predicted development of CFRD in the future [63] , [64] however, a recent larger study showed CGM measures of dysglycemia only correlated with early weight decline at three years, despite detection of glucose abnormalities missed by the OGTT at baseline [87] . In PwCF, diverse epidemiological [21] , [88] , genetic [88] , [89] , therapeutic [90] ) and clinical [16] factors may impact glycemia causing bidirectional changes in glucose levels, which have been detected on both OGTT [21] and CGM [57] . This complex continuum of glucose abnormalities governed by incompletely understood regulatory mechanisms such as the dynamic sensitivity of pancreatic β-cells to changes in glucose concentrations [86] coupled with heterogeneity of PwCF makes it challenging to define glycemia and its effects, regardless of the measurement tool used.…”

Coming Full Circle: Reflections and Inspirations from a Cystic Fibrosis Patient Scientist Panel

“…23 Our positionality statements accompanying this article also reflect specific persistent gaps in CF research and implementation of findings. Subsequent ResearchCon events have consciously centered issues of racial/ethnic/cultural 24 and sex/gender/sexuality justice 25 in science. Deep disparities persist with respect to these characteristics not only in care access 26 and survival outcomes 27 among people living with CF, but also in research participation.…”